EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Chidamide, a Histone Deacetylase Inhibitor, Combined With R‐ GemOx in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma ( TRUST ): A Multicenter, Single‐Arm, Phase 2 Trial

Qihua Zou, Yuchen Zhang, Hui Zhou, Yulin Lai, Yi Cao, Zhiming Li iD, Ning Su, Wenyu Li, Huiqiang Huang, Panpan Liu iD, Xu Ye, Yudan Wu und 13 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.70919 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, 2025. Verfasst von Qihua Zou und 24 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols, Aminopyridines, Histone Deacetylase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Guangzhou Science and Technology Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Histone deacetylase (HDAC) inhibitors demonstrated a synergistic anti‐tumor effect with rituximab and chemotherapy in preclinical studies on diffuse large B‐cell lymphoma (DLBCL). This phase 2 trial aimed to evaluate the efficacy and safety of chidamide, an orally active HDAC inhibitor, plus the R‐GemOx regimen for relapsed/refractory (R/R) DLBCL.

Methods

Patients with transplantation‐ineligible R/R DLBCL received chidamide (20 mg, oral, days 1, 4, 8, 11, 15, and 18), rituximab (375 mg/m 2 , day 1), gemcitabine (1000 mg/m 2 , day 2), and oxaliplatin (100 mg/m 2 , day 2) in a 21‐day cycle for 6 cycles (induction phase), followed by chidamide (20 mg, oral, twice weekly on Mondays and Thursdays) until disease progression or intolerable toxicity (maintenance phase). The primary endpoint was overall response rate (ORR).

Results

Between June 19, 2019 and July 5, 2022, 54 patients were enrolled. The ORR was 59.3% (95% CI: 45.0–72.4). With a median follow‐up of 38.1 months (interquartile range: 19.5–48.2), the median progression‐free survival and overall survival were 7.4 (95% CI: 5.2–14.2) and 23.9 (95% CI: 15.2‐not reached) months, respectively. The most common grade 3/4 treatment‐emergent adverse events (TEAEs) were neutropenia (40.7%), thrombocytopenia (33.3%), and leukopenia (27.8%). Whole‐exome sequencing showed that CREBBP mutations and BTG2 mutations were associated with poor response and survival.

Conclusion

Chidamide plus R‐GemOx demonstrated promising anti‐tumor activity with acceptable toxicities in transplantation‐ineligible R/R DLBCL patients. Patients with CREBBP mutations and BTG2 mutations had inferior response and survival. Trial Registration ClinicalTrials.gov identifier: NCT04022005

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseAntineoplastic Combined Chemotherapy ProtocolsAminopyridinesHistone Deacetylase InhibitorsBenzamidesDeoxycytidineNeoplasm Recurrence, LocalHumansMaleFemaleAgedMiddle AgedAdultRituximabOxaliplatinGemcitabineAged, 80 and overDrug Resistance, Neoplasm

Stichwörter der Autor:innen

R‐GemOxchidamidediffuse large B‐cell lymphomarefractory or relapsedtransplantation‐ineligible

Substanzen

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamideAminopyridinesHistone Deacetylase InhibitorsBenzamidesDeoxycytidineRituximabOxaliplatinGemcitabine

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Experimental Research, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Lymphoma and Hematology, Hunan Cancer Hospital, Changsha, China.
  • Department of Oncology, Guangzhou Chest Hospital, Guangzhou, China.
  • Division of Lymphoma, Department of Clinical Oncology, Guangdong Provincial People's Hospital, Guangzhou, China.

ORCID-Profile: Zhiming Li, Panpan Liu, Peng Sun, Qingqing Cai

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Guangzhou Science and Technology Program
  • Sun Yat-Sen University Clinical Research 5010 Program
  • Beijing Xisike Clinical Oncology Research Foundation

Zitieren

APA

Zou, Q., Zhang, Y., Zhou, H., Lai, Y., Cao, Y., Li, Z., Su, N., Li, W., Huang, H., Liu, P., Ye, X., Wu, Y., Tan, H., Zheng, R., Wu, B., Yang, H., Zhong, L., Lu, Y., Liang, Y., …, & Cai, Q. (2025). Chidamide, a Histone Deacetylase Inhibitor, Combined With R‐ GemOx in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma ( TRUST ): A Multicenter, Single‐Arm, Phase 2 Trial. Cancer Medicine. https://doi.org/10.1002/cam4.70919

Vancouver

Zou Q, Zhang Y, Zhou H, Lai Y, Cao Y, Li Z, et al. Chidamide, a Histone Deacetylase Inhibitor, Combined With R‐ GemOx in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma ( TRUST ): A Multicenter, Single‐Arm, Phase 2 Trial. Cancer Medicine. 2025. doi:10.1002/cam4.70919

BibTeX
@article{Zou2025,
  author = {Zou, Qihua and Zhang, Yuchen and Zhou, Hui and Lai, Yulin and Cao, Yi and Li, Zhiming and Su, Ning and Li, Wenyu and Huang, Huiqiang and Liu, Panpan and Ye, Xu and Wu, Yudan and Tan, Huo and Zheng, Runhui and Wu, Bingyi and Yang, Hui and Zhong, Liye and Lu, Yuhong and Liang, Yang and Sun, Peng and Li, Lirong and Liu, Yingxian and Dai, Danling and Xia, Yi and Cai, Qingqing},
  title = {Chidamide, a Histone Deacetylase Inhibitor, Combined With R‐ GemOx in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma ( TRUST ): A Multicenter, Single‐Arm, Phase 2 Trial},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70919}
}
Kostenlos starten →